Mojibade N. Hassan | Authors

April 15, 2015

Clinical trials of the new thrombopoietin receptor agonists in the management of chemotherapy-induced thrombocytopenia are needed to address concerns about the safety and practical efficacy new agents before we accept them as standard therapies.